Product Images Topiramate

Topiramate is a prescription drug provided in a pack of 30 HD3 units. It has to be stored at a temperature range of 20-26°C (63-77°F), with permissible excursions to 15-30°C (59-86°F), as per the USP standards. The manufacturer of this drug is Cipla USA, Inc., Miami, FL 33156. The package includes a directions for use insert, and the drug should be kept away from children. The drug has been repackaged by RemedyRepack Inc., Indiana, PA 15701, contactable at 724.466.8762. The expires lot number of the drug is not-available.*

Topiramate is a prescription medicine sold in a bottle of 100 HD3 tablets with an NDC code of 70518-2617-01. The manufacturer is Cipla USA, and the medication should be kept away from children. The lot number and expiration date are not specified, and the package insert should be consulted for usage instructions. The medication should be stored between 20-26°C (63-77°F) with brief excursions allowed between 15-30°C (59-86°F). The product has been repackaged by RemedyRepack Inc. located in Indiana, PA.*

Topiramate is a prescription medication packaged by RemedyRepack Inc., Indiana, PA 15701. The medication is manufactured by Cipla USA, Inc., Miami, FL 33156. This medication should be stored at 20-26°C (63-77°F) with permitted excursions to 15-30°C (59-86°F) [See USP]. The direction for use is located within the package insert. The expiration date and lot number are not available. It is important to keep this and all medication out of the reach of children.*

The text describes a graph that shows cumulative rates for time to first seizure for two groups of patients taking different doses of Topiamate. The x-axis shows time in days, and the y-axis shows the cumulative rate. There are 234 patients in the group taking 50mg/day of Topiamate and 236 patients in the group taking 400mg/day.*

The text describes the change in the monthly migraine rate during a double-blind phase of a treatment with Topamax. The treatment involves taking either 100 mg or 200 mg of Topamax per day. The average rate of monthly migraines increased by 56 from baseline. There is also statistical data indicated by *p < 0.010, ** p < 0.001.*